NexImmune (NEXI) IPO Opens 35% Higher

Today's IPO for NexImmune Inc. (NASDAQ: NEXI) opened for trading at $23.01 after pricing its upsized initial public offering of 6,471,000 shares of its common stock at a price to the public of $17.00 per share.

Barclays Capital Inc., Cantor Fitzgerald & Co., Raymond James & Associates, Inc. and Allen & Company LLC are acting as the joint book-running managers for this offering.

NexImmune, based in Gaithersburg, Maryland, is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent and durable immune response that mimics natural biology

You May Also Be Interested In

• Samos Energy prices IPO of 20M units at $10 each on NYSE
• Mercator Acquisition Corp. Announces Closing of $172.5 Million Initial Public Offering
• Nasdaq president says SK Hynix blockbuster IPO to draw foreign firms to US